AstraZeneca plc Upbeat On Revenue Recovery

AstraZeneca plc (LON: AZN) says a return to sales growth should come earlier than expected.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

drugsThe shares of AstraZeneca (LSE: AZN) (NYSE: AZN.US) added 80p to 3,744p during early trade this morning after the pharmaceutical group provided an upbeat assessment of its revenue prospects.

The FTSE 100 member said it continued to believe “a return to growth should come earlier than analyst consensus currently forecasts“, and that it now expects 2017 group revenues to be “broadly in line” with 2013 revenues.

AstraZeneca added that it would provide further details about its progress within its 2013 annual results, due to be published on 6 February.

During March last year, the blue chip claimed it could “significantly exceed” the then market consensus for 2018 revenues of $21.5bn.

AstraZeneca’s revenues fell 17% to $28bn during 2012 and dropped 9% to $19bn during the first nine months of 2013. Several products losing their patents and suffering generic competition have caused the top-line trouble.

Today’s statement from AstraZeneca also revealed the group’s late-stage pipeline consists of 11 Phase III and 27 Phase II programmes.

Prior to today, City experts were expecting AstraZeneca’s upcoming annual results to show earnings at 307p per share and a dividend of roughly 180p per share.

Following this morning’s price movement, the shares may therefore trade on a P/E of 12 and yield a possible 4.8%.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Maynard does not own any share mentioned in this article.

More on Investing Articles

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Here’s what needs to happen for the Lloyds share price to reach £1

The Lloyds share price is up 40% since the start of the year, but could it continue to climb all…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

Here’s how investing £10,000 a year can lead to annual passive income of £67,000

This writer explores two different stock market approaches to building up a sizeable passive income figure. Both can generate significant…

Read more »

Senior woman potting plant in garden at home
Investing Articles

Start putting £700 each month into a SIPP to try and retire as a millionaire!

By investing £700 a month using a SIPP, even someone in their 40s with no savings might retire a millionaire.…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

Move over premium bonds: here’s how to earn passive income on the stock market

Premium bonds may have been good to some Britons, but the average yield is far below what most passive income…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

3 cheap dividend stocks I bought for a lifetime of passive income

There are plenty of cash-rich dividend stocks at juicy discounts today. Zaven Boyrazian explores three that he's added to his…

Read more »

Middle aged businesswoman using laptop while working from home
Investing Articles

With a 10.1% dividend yield, could this FTSE 250 share be an income gold mine?

At 10.1%, this unloved FTSE income stock has one of the highest dividend yields on the market. And if conditions…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Here’s what Warren Buffett says will be the ultimate growth industry!

Warren Buffett is well aware of the growth potential artificial intelligence offers, but in his mind, it’s not the biggest…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

Here’s a high-potential stock to consider buying in July!

This company's undergoing a transition in order to make it a leaner and more focused business. Dr James Fox explores…

Read more »